Organovo (ONVO) Stock Forecast, Price & News

Organovo (NASDAQ:ONVO) Frequently Asked Questions

Is Organovo a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Organovo stock.
View analyst ratings for Organovo or view top-rated stocks.

When is Organovo's next earnings date?

Organovo is scheduled to release its next quarterly earnings announcement on Tuesday, June 21st 2022.
View our earnings forecast for Organovo.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) released its earnings results on Thursday, August, 8th. The medical research company reported ($1.00) EPS for the quarter, hitting analysts' consensus estimates of ($1.00). The medical research company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.77 million.
View Organovo's earnings history.

When did Organovo's stock split? How did Organovo's stock split work?

Shares of Organovo reverse split before market open on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of Organovo stock prior to the reverse split would have 5 shares after the split.

Who are Organovo's key executives?

Organovo's management team includes the following people:

• Mr. Keith E. Murphy, Exec. Chairman & Principal Exec. Officer (Age 50, Pay $397.18k)
• Dr. Jeffrey N. Miner, Chief Scientific Officer (Age 60, Pay $221.09k)
• Mr. Thomas Einar Jurgensen J.D., MS, Gen. Counsel & Corp. Sec. (Age 65, Pay $264.86k)
• Mr. Thomas P. Hess CPA, MBA, Chief Financial Officer (Age 58)
• Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications
• Dr. Curtis M. Tyree Ph.D., Sr. VP of Strategy & Bus. Devel.

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo CEO Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among Organovo's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Organovo's key competitors?

Some companies that are related to Organovo include Rubius Therapeutics (RUBY), TCR2 Therapeutics (TCRR), SQZ Biotechnologies (SQZ), SAB Biotherapeutics (SABS), Aziyo Biologics (AZYO), BioAtla (BCAB), TScan Therapeutics (TCRX), aTyr Pharma (LIFE), Axcella Health (AXLA), Harpoon Therapeutics (HARP), Adverum Biotechnologies (ADVM), Miromatrix Medical (MIRO), Elevation Oncology (ELEV), Vigil Neuroscience (VIGL) and Curis (CRIS).
View all of ONVO's competitors.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK).

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Who are Organovo's major shareholders?

Organovo's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (3.52%), Vanguard Group Inc. (3.10%), Renaissance Technologies LLC (1.82%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%).
View institutional ownership trends for Organovo.

Which major investors are selling Organovo stock?

ONVO stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, ARK Investment Management LLC, and Simplex Trading LLC.
View insider buying and selling activity for Organovo or view top insider-selling stocks.

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $2.67.

How much money does Organovo make?

Organovo has a market capitalization of $23.25 million and generates $2.20 million in revenue each year. The medical research company earns $-16.83 million in net income (profit) each year or ($1.390010) on an earnings per share basis.

How many employees does Organovo have?

Organovo employs 12 workers across the globe.

What is Organovo's official website?

The official website for Organovo is www.organovo.com.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at (858) 224-1000 or via email at [email protected].